In his article “Preliminary Injunctions in German Pharmaceutical Patent Litigation”, published in the Newsletter of the AIPLA Chemical Practice Committee, Spring 2026, Volume 14, Issue 1, Dr Marco Stief, examines the growing importance of preliminary injunctions in pharmaceutical patent disputes in Germany.
He explains why preliminary relief in the pharma sector is no longer a peripheral or purely defensive tool, but has become a key instrument for originators seeking to prevent generic and biosimilar launches – and how the combination of swift procedures, immediate enforceability and Germany’s continued focus on injunctive relief makes the jurisdiction particularly attractive for pharmaceutical litigation.
